Business Description
Exagen Inc
NAICS : 541380
SIC : 8071
ISIN : US30068X1037
Share Class Description:
XGN: Ordinary SharesTotal Employee Number:
220Description
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.85 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 1.76 | |||||
Debt-to-EBITDA | -1.99 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.8 | |||||
Beneish M-Score | -2.96 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5 | |||||
3-Year EBITDA Growth Rate | 37.5 | |||||
3-Year EPS without NRI Growth Rate | 29.3 | |||||
3-Year FCF Growth Rate | 32.3 | |||||
3-Year Book Growth Rate | -33.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.93 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.39 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.11 | |||||
9-Day RSI | 58.68 | |||||
14-Day RSI | 57.43 | |||||
3-1 Month Momentum % | 43 | |||||
6-1 Month Momentum % | -28.74 | |||||
12-1 Month Momentum % | -38.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.47 | |||||
Quick Ratio | 3.47 | |||||
Cash Ratio | 1.71 | |||||
Days Sales Outstanding | 71.22 | |||||
Days Payable | 48.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.5 | |||||
Shareholder Yield % | -1.93 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.32 | |||||
Operating Margin % | -20.65 | |||||
Net Margin % | -29.49 | |||||
EBITDA Margin % | -18.66 | |||||
FCF Margin % | -20.66 | |||||
OCF Margin % | -19.55 | |||||
ROE % | -130.18 | |||||
ROA % | -37.09 | |||||
ROIC % | -73.78 | |||||
3-Year ROIIC % | -2082.21 | |||||
ROC (Joel Greenblatt) % | -88.21 | |||||
ROCE % | -36.16 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.58 | |||||
PB Ratio | 8 | |||||
Price-to-Tangible-Book | 7.99 | |||||
EV-to-EBIT | -7.97 | |||||
EV-to-Forward-EBIT | -8.04 | |||||
EV-to-EBITDA | -9.39 | |||||
EV-to-Forward-EBITDA | -12.66 | |||||
EV-to-Revenue | 1.75 | |||||
EV-to-Forward-Revenue | 1.94 | |||||
EV-to-FCF | -8.48 | |||||
Price-to-GF-Value | 1.6 | |||||
| Price-to-Net-Current-Asset-Value | 19.18 | |||||
Earnings Yield (Greenblatt) % | -12.55 | |||||
FCF Yield % | -12.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exagen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 68.383 | ||
| EPS (TTM) ($) | -0.89 | ||
| Beta | 2.3545 | ||
| 3-Year Sharpe Ratio | 0.52 | ||
| 3-Year Sortino Ratio | 1.06 | ||
| Volatility % | 102.15 | ||
| 14-Day RSI | 57.43 | ||
| 14-Day ATR ($) | 0.354627 | ||
| 20-Day SMA ($) | 4.506 | ||
| 12-1 Month Momentum % | -38.36 | ||
| 52-Week Range ($) | 2.59 - 12.23 | ||
| Shares Outstanding (Mil) | 24.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exagen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exagen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | In 22 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 21 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 4.20 (-5.19%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 08:30 | 2.95 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 2.95 (+0.00%) | ||
| Roth Capital Conference | 2026-03-23 | 2.78 (-13.26%) | ||
| KeyBank Capital Markets Healthcare Forum - Virtual | 2026-03-17 15:00 | 3.16 (+2.93%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-10 08:30 | 3.38 (+4.32%) |
Show
Entries
Exagen Inc Frequently Asked Questions
What is Exagen Inc(XGN)'s stock price today?
The current price of XGN is $4.80. The 52 week high of XGN is $12.23 and 52 week low is $2.59.
When is next earnings date of Exagen Inc(XGN)?
The next earnings date of Exagen Inc(XGN) is 2026-07-29 Est..
Does Exagen Inc(XGN) pay dividends? If so, how much?
Exagen Inc(XGN) does not pay dividend.
Guru Commentaries on NAS:XGN
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Exagen Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers